Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tagrid Adili

Neurology Port St Lucie, FL Medical Doctor

NPI 1093820417 CMS profile 4912

463 Nw Prima Vista Blvd, Port St Lucie, FL 34983

Open in the dashboard

General payments

$13,360

537 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tagrid Adili of Port St Lucie, FL is reported in the CMS Open Payments database as having received $13,360 across 537 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,090 71
2024 General $2,963 98
2023 General $1,368 55
2022 General $2,320 100
2021 General $1,028 41
2020 General $1,591 80
2019 General $2,000 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tagrid Adili
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Tagrid Adili were reported at $2,090. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Tagrid Adili Neurology median Middle half National median
2019 $2,000 $474 $118–$2,177 $163
2020 $1,591 $367 $82–$2,309 $114
2021 $1,028 $438 $104–$2,547 $132
2022 $2,320 $442 $103–$2,388 $149
2023 $1,368 $464 $119–$2,312 $160
2024 $2,963 $468 $119–$2,323 $164
2025 $2,090 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,361 50 payments
  2. Lilly USA, LLC $955 44 payments
  3. Biogen, Inc. $840 38 payments
  4. Genzyme Corporation $765 19 payments
  5. Harmony Biosciences LLC $651 16 payments
  6. Jazz Pharmaceuticals Inc. $627 27 payments
  7. EMD Serono, Inc. $626 25 payments
  8. Eisai Inc. $572 15 payments
  9. Amgen Inc. $563 17 payments
  10. Alexion Pharmaceuticals, Inc. $561 15 payments
  11. Other $5,838 271 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,013 529 payments
  2. Education $320 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,040 38 payments
  2. QULIPTA $690 27 payments
  3. AIMOVIG $610 20 payments
  4. Leqembi $572 15 payments
  5. EMGALITY $472 28 payments
  6. GOCOVRI $415 23 payments
  7. Briviact $414 17 payments
  8. Austedo XR $384 8 payments
  9. ULTOMIRIS $382 11 payments
  10. NURTEC ODT $349 18 payments
  11. Other $8,972 399 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,490

Median for Neurology: 833

Drug cost

$795,233

Median for Neurology: $202,670

Branded share of claims

10.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xyrem Sodium Oxybate Brand 12 $263,190
Sodium Oxybate Generic 11 $222,246
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 11 $113,889
Qulipta Atogepant Brand 22 $38,108
Aimovig Autoinjector Erenumab-Aooe Brand 33 $27,840
Neupro Rotigotine Brand 14 $25,328
Briviact Brivaracetam Brand 14 $20,874
Vimpat Lacosamide Brand 13 $19,558
Emgality Pen Galcanezumab-Gnlm Brand 11 $14,057
Duloxetine Hcl Generic 527 $13,277

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$73,465

Medicare's payments for the services billed

Medicare patients

295

Average age 76

Services billed

737

164 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Depression 39%
Diabetes 38%
Ischemic heart disease 37%
Chronic kidney disease 26%
COPD 25%
Alzheimer's or dementia 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $331
$331 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $251
$251 — —
WAKIX
  • Harmony Biosciences LLC $212
$212 — —
UBRELVY
  • AbbVie, Inc. $209
$209 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $176
$176 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record